SUBSTITUTE FORM PTO-1449 (MODIFIED)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE Attorney Docket No.

50304/054001

Serial No.

10/519,756

INFORMATION DISCLOSURE

Applicant

Neyts et al.

STATEMENT BY APPLICANT

(Use several sheets if necessary)

Filing Date

December 30, 2004

Group

1617

(37 C.F.R. § 1.98(b))

IDS Filed

March 20, 2007

Examiner's Initials	Document Number	Publication Date	Patentee or Applicant	Class	Subclass	Filing Date (If Appropriate)
/SW/	3,985,891	10/12/76	Kutter et al.			
00000000	4,565,816	01/21/86	Neumann			
	4,692,443	09/08/87	Katner			
200000000	4,804,658	02/14/89	Manley et al.			
000000000	4,914,108	04/03/90	Khanna et al.			
000000000	4,988,707	01/29/91	Stealey et al.			
	4,990,518	02/05/91	Khanna et al.			
0000	5,019,581	05/28/91	Khanna et al.			
000000000000000000000000000000000000000	5,057,517	10/15/91	Johnston et al.			
	5,137,896	08/11/92	Van Daele			
2000	5,208,242	05/04/93	Khanna et al.			
000000000000000000000000000000000000000	5,227,384	07/13/93	Khanna et al.			
00000000	5,302,601	04/12/94	Khannal et al.			
000000000	5,332,744	07/26/94	Chakravarty et al.			
000	5,374,638	12/20/94	Dhanoa et al.			
333333333	5,405,964	04/11/95	Mederski et al.			
000000000000000000000000000000000000000	5,438,063	08/01/95	Osswald et al.			"
	5,486,525	01/23/96	Summers, Jr. et al.			
1/	5,587,372	12/24/96	Aszodi et al.			
V	5,607,944	03/04/97	Linz et al.			<u> </u>
/SW/	6,329,381 B1	12/11/01	Kurimoto et al.			

EXAMINER

/Shengjun Wang/

DATE CONSIDERED

12/05/2008

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.

MAR 2 3 2007

SUBSTITUTE FORM PTO-1449 (MODIFIED) Attorney Docket No. 50304/054001 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE Serial No. 10/519,756 **Applicant** Neyts et al. INFORMATION DISCLOSURE Filing Date STATEMENT BY APPLICANT December 30, 2004 (Use several sheets if necessary) Group 1617 (37 C.F.R. § 1.98(b)) **IDS Filed** March 20, 2007

/SW/	6,479,508 B1	11/12/02	Beaulieu et al.			
0000						
***************************************	6,492,384 B1	12/10/02	Mederski et al.			
	6,770,666 B2	08/03/04	Hashimoto et al.			
900000000	7,112,600 B1	09/26/06	Hashimoto et al.			
000000	2004/0082635 A1	04/29/04	Hashimoto et al.			
00000000	2003/0108862 A1	06/12/03	Kukolj et al.			
V	2004/0097438 A1	05/20/04	Hashimoto et al.			
/SW/	2004/0097574 A1	05/20/04	Marshall			
	FOREIG	N PATENT OR I	PUBLISHED FOREIGN PATENT AF	PPLICATIO	DN	
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
/SW/	CA 2 357 771	07/13/00	Canada			
9000000	DE 42 11 474 A1	10/07/93	Germany	!		No
	DE 42 30 464 A1	03/17/94	Germany			No
00000000	DE 42 36 026 A1	04/28/94	Germany			No
20000000	DE 43 09 969 A1	09/29/94	Germany			No
00000000	DE 43 18 813 A1	12/08/94	Germany			No
0000000	EP 0 076 530 B1	04/13/83	EPO			
20000000	EP 0 138 552 A2	04/24/85	EPO			
	EP 0 232 937 A2	08/19/87	EPO .			
900	EP 0 300 726 A1	01/25/89	EPO			
	EP 0 300 726 B1	01/25/89	EPO			
V	EP 0 344 414 A1	12/06/89	EPO			
/SW/	EP 0 344 414 B1	12/06/89	EPO			

EXAMINER	/Shengjun Wang/	DATE CONSIDERED	12/05/2008
EXAMINER: In	nitial citation considered. Draw line through citation	on if not in conformance and	not considered. Include conv of this

form with the next communication to applicant.

SUBSTITUTE FORM PTO-1449 (MODIFIED)

(37 C.F.R. § 1.98(b))

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE Attorney Docket No.

50304/054001

Serial No. Applicant

10/519,756 Neyts et al.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Filing Date

Group

December 30, 2004

1617

(Use several sheets if necessary)

IDS Filed

March 20, 2007

/SW/	EP 0 462 009 B1	12/18/91	EPO	Abstract Only
3 000000	EP 0 510 260 A2	10/28/92	EPO	
00000000	EP 0 605 836 A1	07/13/94	EPO	
200000000000000000000000000000000000000	EP 0 706 795 A2	04/17/96	EPO	
80000000	EP 1 132 381 A1	09/12/01	EPO	
	EP 1 162 196 A1	12/12/01	EPO	
000000000000000000000000000000000000000	EP 1 400 241 A1	03/24/04	EPO	
000000	GB 2 158 440 A	11/13/85	Great Britain	
0000000	GB 2 264 115 A	08/18/93	Great Britain	
	HU 78019	05/28/95	Hungary	
	SU 813921 A	12/23/86	Soviet Union	No
	SU 851940 A	04/30/88	Soviet Union	No
0000000	SU 860463 A1	05/27/98	Soviet Union	Yes - Abstrac
00000000	SU 1048742 A	12/23/86	Soviet Union	No
00000000	WO 92/22556 A1	12/23/92	WIPO	
00000000	WO 93/02080 A1	02/04/93	WIPO	
	WO 93/14072 A1	07/22/93	WIPO	
2000000	WO 93/16075 A1	08/19/93	WIPO	
0000000	WO 94/12461 A1	06/09/94	WIPO	
000000000000000000000000000000000000000	WO 94/29321 A1	12/22/94	WIPO	
200000000	WO 95/02597 A1	01/26/95	WIPO	
	WO 95/16687 A1	06/22/95	WIPO	
V	WO 96/11192 A1	04/18/96	WIPO	
/SW/	WO 96/12703 A1	05/02/96	WIPO	

EXAMINER

/Shengjun Wang/

DATE CONSIDERED

12/05/2008

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.

MAR 2 3 2007 SUBSTITUTE FORM PTO-1449 Sheet <u>4</u> of <u>5</u> Attorney Docket No. 50304/054001 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE Serial No. 10/519,756 **Applicant** Neyts et al. INFORMATION DISCLOSURE STATEMENT BY APPLICANT Filing Date December 30, 2004 (Use several sheets if necessary) Group 1617 (37 C.F.R. § 1.98(b)) **IDS Filed** March 20, 2007

/SW/	WO 99/27929 A1	06/10/99	WIPO		<u> </u>
8					
	WO 00/20416 A1	04/13/00	WIPO		Abstract Only
	WO 00/39127 A1	07/06/00	WIPO		
	WO 00/40583 A2	07/13/00	WIPO		Abstract Only
800	WO 00/40586 A1	07/13/00	WIPO		Abstract Only
20000000	WO 01/60315 A2	08/23/01	WIPO		
0000000	WO 01/85172 A1	11/15/01	WIPO		
000000	WO 02/04425 A2	01/17/02	WIPO		
	WO 02/057425 A2	07/25/02	WIPO		
	WO 03/007945 A1	01/30/03	WIPO		
00000000	WO 03/010140 A2	02/06/03	WIPO		
000000	WO 03/010141 A2	02/06/03	WIPO		
0000000	W0 03/026587 A2	04/03/03	WIPO		
	W0 04/005286 A2	01/15/04	WIPO		
V	W0 04/005286 A3	01/15/04	WIPO		
/SW/	WO 04/019935 A1	03/11/04	WIPO		
	OTHER DOCUME	ENTS (INCLUDI	NG AUTHOR, TITLE, DATE, PLAC	E OF PUBLICAT	TION)
/SW/	/SW/ Akamatsu et al., "New Efficient Route for Solid-Phase Synthesis of Benzimidazole Derivatives," <i>J. Comb. Che</i> 4:475-483 (2002).				atives," J. Comb. Chem.
/SW/	7.550 (2000).				
/SW/				J. Chem. Soc. B: Phys.	
/SW/	Barlin and Fenn, "A Carbon-13 Nuclear Magnetic Resonance Study of Protonation in Imidazo[4,5-c]pyridines, Aust. J. Chem. 34:1341-1344 (1981).			idazo[4,5-c]pyridines,"	

LE	EXAMINER	/Shengjun Wang/	DATE CONSIDERED	12/05/2008				
	EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.							

MAR 2 3 2007 Sheet <u>5</u> of <u>5</u> Attorney Docket No. 50304/054001 SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (MODIFIED) PATENT AND TRADEMARK OFFICE Serial No. 10/519,756 Applicant Neyts et al. INFORMATION DISCLOSURE STATEMENT BY APPLICANT Filing Date December 30, 2004 (Use several sheets if necessary) Group 1617 (37 C.F.R. § 1.98(b)) **IDS Filed** March 20, 2007

/SW/	Barlin and Fenn, "The Preparation and 1H NMR Spectra of Some N-Methylpurines and Related Compounds," Aust. J. Chem. 36:633-638 (1983).
000000000000000000000000000000000000000	Barraclough et al., "An Adventitious Synthesis of a 5-Methylimidazo[4,5-c]pyridine Derivative," <i>Tet. Lett.</i> 27:5997-6000 (1986).
	Barraclough et al., "Inotropic "A" Ring Substituted Sulmazole and Isomazole Analogues," <i>J. Med. Chem.</i> 33:2231-2239 (1990).
	Brown et al., "Purine Analogues as Amplifiers of Phleomycin. V. Thioethers of Several Heterocyclic Systems with One or Two Rings," Aust. J. Chem. 32:2713-2726 (1979).
000000000000000000000000000000000000000	Cleve et al., "Derivate des Imidazo[4,5-b]- und Imidazo[4,5-c]pyridins," Liebigs Ann. Chem. 747:158-171 (1971).
000000000000000000000000000000000000000	Curtin et al., "Discovery and Evaluation of a Series of 3-Acylindole Imidazopyridine Platelet-Activating Factor Anatagonists," J. Med. Chem. 41:74-95 (1998).
***************************************	Kiyama et al., "Synthesis and Evaluation of Novel Nonpeptide Angiotesin II Receptor Antagonists: Imidazo[4,5-c]pyridine Derivatives with an Aromatic Substituent," <i>Chem. Pharm. Bull.</i> 43:450-460 (1995).
000000000000000000000000000000000000000	Mederski and Pachler, "Synthesis and Structural Assignment of Some N-Substituted Imidazopyridine Derivatives," <i>Tetrahedron</i> 48:10549-10558 (1992).
000000000000000000000000000000000000000	Robertson et al., "Structure-Activity Relationships of Arylimidazopyridine Cardiotonics: Discovery and Inotropic Activity of 2-[2-Methoxy-4-(methylsulfinyl)phenyl]-1 <i>H</i> -imidazo[4,5- <i>c</i>]pyridine," <i>J. Med. Chem.</i> 28:717-727 (1985).
000000000000000000000000000000000000000	Savarino et al., "Spectral Behaviour of Linked Heterocyclic Systems and Related Dyes," Spectrochim. Acta A: Mol. Biomol. Spectrosc. 49A:1379-1393 (1993).
200000000000000000000000000000000000000	Stanovnik et al., "Methylation of Heterocyclic Compounds Containing NH, SH, and/or OH Groups by Means of N,N-Dimethylformamide Dimethyl Acetal," <i>Aust. J. Chem.</i> 34:1729-1738 (1981).
000000000000000000000000000000000000000	Vassilev et al., "Authentic and Chimeric Full-Length Genomic cDNA Clones of Bovine Viral Diarrhea Virus That Yield Infectious Transcripts," <i>J. Virol.</i> 71:471-478 (1997).
000000000000000000000000000000000000000	Wang et al., "Non-Nucleoside Analogue Inhibitors Bind to an Allosteric Site on HCV NS5B Polymerase. Crystal Structures and Mechanism of Inhibition," <i>J. Biol. Chem.</i> 278:9489-9495 (2003).
	Yutilov et al., "Synthesis and Antiviral Activity of Spinaceamine," Khim. Farm. Zh. 23:56-59 (1989).
V	Zhang, "Inhibitors of Hepatitis C A Review of the Recent Patent Literature," IDrugs 5:154-158 (2002).
/SW/	International Preliminary Examination Report (PCT/BE03/00117) (mailed 3 September, 2004).

EXAMINER	/Shengjun Wang/	DATE CONSIDERED	12/05/2008			
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this						

form with the next communication to applicant.